United Therapeutics Corp
UTHR
$503.86
-0.58%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease, with a portfolio that includes Tyvaso DPI, Remodulin, Orenitram, Adcirca, and Unituxin. The company is a market leader in the PAH space, leveraging its expertise in the prostacyclin pathway and the treprostinil molecule to maintain a dominant position. Currently, the investor narrative centers on the FDA's acceptance of the NDA filing for ralinepag, a potential new PAH treatment, and the positive Phase 3 data for Tyvaso in a new lung disease indication, which could significantly expand its market opportunity. These catalysts are driving optimism about future revenue growth, though competition from other PAH players like Liquidia and Insmed remains a key debate.…
UTHR
United Therapeutics Corp
$503.86
Related headlines
Investment Opinion: Should I buy UTHR Today?
Rating: Buy. United Therapeutics is a profitable biotech with a dominant position in PAH, trading at a reasonable valuation with significant upside to analyst targets. The consensus recommendation is 'buy' with an average target price of $664.33, implying 36.2% upside. The thesis is supported by a strong pipeline (ralinepag, Tyvaso expansion) that could reignite growth, and a solid balance sheet with minimal debt.
Sign up to view all
UTHR 12-Month Price Forecast
The AI assessment is cautiously bullish, given the attractive valuation and pipeline potential. The key risk is revenue stagnation, but the low PE and strong balance sheet limit downside. If ralinepag is approved and Tyvaso expansion succeeds, the stock could re-rate higher. Conversely, if pipeline setbacks occur, the stock could decline to the low target. The stance would be upgraded to high confidence if revenue growth turns positive, and downgraded to neutral if regulatory delays occur.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $664.33 and implied upside of +31.9% versus the current price.
Average Target
$664.33
0 analysts
Implied Upside
+31.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$515 - $725
Analyst target range
United Therapeutics is covered by 12 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.64 (where 1 is strong buy and 5 is sell). The average target price is $664.33, implying an upside of 36.2% from the current price of $487.61. The distribution of ratings is bullish, with a mix of Buy and Outperform ratings from firms like RBC Capital and TD Cowen, while some like B of A Securities maintain a Neutral stance. The high target of $725 suggests that some analysts see significant upside, likely driven by the success of Tyvaso in new indications and the ralinepag approval, while the low target of $515 is still above the current price, indicating that even the most bearish analyst sees some value. The wide range between low and high targets ($210) reflects uncertainty about the pipeline's commercial potential and competitive dynamics. Recent actions show a mix of upgrades and reiterations, with Wells Fargo upgrading from Equal Weight to Overweight in May 2026, indicating growing optimism, while others have maintained their positions, suggesting a generally positive but cautious outlook.
Bulls vs Bears: UTHR Investment Factors
United Therapeutics presents a balanced bull-bear case. The bull side is supported by a dominant PAH franchise with high margins, a strong balance sheet, and multiple pipeline catalysts that could drive growth. The bear side highlights a revenue plateau, competitive pressures, and a rich PS ratio that leaves little room for error. Currently, the bull case has slightly stronger evidence given the low PE and analyst upside, but the key tension lies in whether pipeline catalysts (ralinepag approval, Tyvaso expansion) can reignite revenue growth. If they succeed, the stock could re-rate higher; if they fail, the valuation premium could compress.
Bullish
- Dominant PAH franchise with high margins: United Therapeutics generates robust revenue from its PAH portfolio, led by Tyvaso DPI ($457.5M in Q1 2026). Gross margin is exceptionally high at 82.93%, reflecting strong pricing power in rare disease therapies. Net margin of 35.18% demonstrates efficient operations despite R&D investments.
- Pipeline catalysts: ralinepag and Tyvaso expansion: FDA accepted the NDA filing for ralinepag, a potential new PAH treatment, and positive Phase 3 data for Tyvaso in a new lung disease indication could significantly expand the market opportunity. These catalysts are expected to reignite revenue growth, which has plateaued in recent quarters.
- Attractive valuation with 36% upside to targets: Trading at a trailing PE of 16.17x, below the S&P 500 average of ~20x, the stock is reasonably valued for a profitable biotech. Analyst consensus is 'buy' with an average target of $664.33, implying 36.2% upside from the current price of $487.61. Even the low target of $515 is above current price.
- Strong balance sheet with minimal debt: Debt-to-equity ratio is a mere 0.0053, indicating virtually no leverage. Current ratio of 6.60 shows ample liquidity to fund pipeline development and potential acquisitions. This financial strength provides a cushion against operational setbacks.
Bearish
- Revenue plateau in core franchise: Q1 2026 revenue of $781.5M declined 1.62% YoY, breaking a trend of sequential growth in 2025. This suggests the core PAH market is maturing, and growth now depends on pipeline success, which carries regulatory and commercial risks.
- Competitive threats from Liquidia and Insmed: Liquidia's Yutrepia is gaining momentum in the PAH space, and intense competition from UTHR and INSM could limit long-term growth for all players. Insmed's pipeline also poses a threat to UTHR's market share in prostacyclin-based therapies.
- High PS ratio at 6.78x: The price-to-sales ratio of 6.78x is elevated compared to historical averages, indicating the market is paying a premium for sales. This could lead to valuation compression if revenue growth fails to accelerate, especially given the recent revenue decline.
- Recent price weakness and negative momentum: The stock has fallen 11.32% over the past three months and 6.05% in the last month, underperforming the S&P 500. It is currently 20% below its 52-week high of $609.35, suggesting waning investor enthusiasm despite positive news.
UTHR Technical Analysis
United Therapeutics is currently in a pullback phase within a longer-term uptrend. Over the past year, the stock has gained 28.16%, but it has retreated from its 52-week high of $609.35 to the current price of $487.61, which is only 80% of the 52-week range (calculated as (487.61-375.61)/(609.35-375.61) = 0.48, so it sits at 48% of the range). This positioning suggests the stock is in the middle of its range, indicating a potential consolidation after a strong run, rather than a breakdown or a new high. The 52-week low of $375.61 provides a significant support level, while the high of $609.35 acts as resistance.
Beta
0.56
0.56x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$395-$609
Price range past year
Annual Return
+27.1%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -2.3% | -1.6% |
| 3m | -7.7% | +2.2% |
| 6m | -6.0% | +14.4% |
| 1y | +27.1% | +16.2% |
| ytd | +1.4% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
United Therapeutics reported revenue of $781.5 million for Q1 2026, a slight decline of 1.62% year-over-year, breaking a trend of sequential growth seen in 2025 (Q1: $794.4M, Q2: $798.6M, Q3: $799.5M, Q4: $790.2M). The revenue dip is modest, but it indicates a plateau in the core PAH franchise, with Tyvaso contributing $457.5 million, Remodulin $126.6 million, and Orenitram $135.6 million. The company's growth is now dependent on new indications like the potential Tyvaso expansion into other lung diseases and the ralinepag NDA, which could reignite growth. Net income for Q1 2026 was $274.9 million, with a net margin of 35.18%, down from the 46.10% in Q4 2025 but still robust. Gross margin remains high at 82.93%, reflecting the company's strong pricing power in rare disease therapies. Operating margin was 41.69%, showing efficient cost management despite R&D investments of $138.2 million. The company is highly profitable, with EPS of $6.32 for the quarter, and has consistently generated positive net income over the past eight quarters, with margins ranging from 38.9% to 46.1%.
Quarterly Revenue
$781500000.0B
2026-03
Revenue YoY Growth
-1.6%
YoY Comparison
Gross Margin
82.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given that United Therapeutics has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 16.17x, while the forward PE is 16.24x, indicating that the market expects earnings to remain stable, with no significant growth premium. This is a low multiple for a biotech company with a strong pipeline, suggesting the market is pricing in limited growth or potential risks. The PEG ratio of 1.16x implies that the stock is fairly valued relative to its expected earnings growth. Compared to the industry average, United Therapeutics trades at a discount; for example, the sector average PE is typically higher, but without specific data, we can note that the company's PE is below the S&P 500 average of around 20x, indicating a value-oriented valuation. Historically, the stock's PE has ranged from 8.75x in Q1 2024 to 24.44x in Q2 2022, with the current 16.17x sitting near the middle of that range, suggesting it is not at an extreme. The PS ratio of 6.78x is higher than the historical average of around 20x, but this is due to the recent price appreciation and stable revenue, indicating that the market is paying a premium for sales, which could be justified by the company's high margins and pipeline potential.
PE
16.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks include a revenue plateau, as Q1 2026 revenue declined 1.62% YoY, indicating that the core PAH market is maturing. The company's net margin, while robust at 35.18%, is down from 46.10% in Q4 2025, suggesting potential cost pressures or product mix shifts. Despite high gross margins of 82.93%, the company's dependence on Tyvaso (58.5% of revenue) creates concentration risk; any disruption to Tyvaso sales would materially impact earnings. However, the balance sheet is strong with a debt-to-equity ratio of 0.0053 and a current ratio of 6.60, providing ample liquidity to weather operational challenges.